Danaher Corporation (DHR)

NYQ · Health Care · Diagnostics & Research
By Alex · Tickerpine
$196.19
+3.38 (+1.75%)
Price — last 10 years monthly, dividend-adjusted · hover for detail
Market Cap
$138.86B
P/E (TTM)
38.0
Forward P/E
21.3
EPS (TTM)
$5.16
ROE
7.08%
Profit Margin
14.89%
Revenue Growth
3.70%
Dividend Yield
0.82%
Beta
0.83
52W High
$242.80
52W Low
$160.93
Analyst Target
$242.35
What would an investment in DHR be worth today?
Run DHR through our free historical return calculator.
Calculate DHR returns →

Congress trading in DHR

21 members of Congress have disclosed trading DHR — 23 purchases and 12 sales worth an estimated $728,000. Most recent disclosure: Dec 18, 2025.

See who in Congress traded DHR →

About Danaher Corporation

Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. The company operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, and aseptic fill finish; single-use hardware, consumables, and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services for diagnostic and assay development; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; bioanalytical measurement systems; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; genome sample preparation; microscopes; protein consumables; filtration products; and genomic medicines, such as custom nucleic acid products, and plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, GENEDATA, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX, and SCIEX brands. The Diagnostics segment offers clinical instruments, consumables, software, and services that hospitals, physicians' offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was incorporated in 1969 and is headquartered in Washington, the District Of Columbia.

Company website ↗

DHR Key Statistics

Previous Close$192.81P/E Ratio38.0
Market Cap$138.86BPEG Ratio1.26
Revenue (TTM)$24.78BROE7.08%
Gross Margin58.99%ROA4.19%
Debt / Equity37.2Employees58,000

DHR in plain English

Compare DHR with peers

DHR vs LLYEli Lilly and Company $1,208.12 DHR vs JNJJohnson & Johnson $254.66 DHR vs ABBVAbbVie Inc. $253.35 DHR vs UNHUnitedHealth Group Incorporated $427.89 DHR vs MRKMerck & Co., Inc. $128.66

Data last refreshed from public sources. Figures may be delayed. Not investment advice.